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Epitope mapping and kinetics of 
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virus of mice in the C57BL/6 strain
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Andrew J. Easton6, Gert Van Isterdael1,4, Sophie Janssens1,2,3, Bart N. Lambrecht1,2,3 & Mary J. 
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Pneumonia virus of mice (PVM) infection has been widely used as a rodent model to study the closely 
related human respiratory syncytial virus (hRSV). While T cells are indispensable for viral clearance, 
they also contribute to immunopathology. To gain more insight into mechanistic details, novel tools 
are needed that allow to study virus-specific T cells in C57BL/6 mice as the majority of transgenic 
mice are only available on this background. While PVM-specific CD8 T cell epitopes were recently 
described, so far no PVM-specific CD4 T cell epitopes have been identified within the C57BL/6 strain. 
Therefore, we set out to map H2-IAb-restricted epitopes along the PVM proteome. By means of in silico 
prediction and subsequent functional validation, we were able to identify a MHCII-restricted CD4 T 
cell epitope, corresponding to amino acids 37–47 in the PVM matrix protein (M37–47). Using this newly 
identified MHCII-restricted M37–47 epitope and a previously described MHCI-restricted N339–347 epitope, 
we generated peptide-loaded MHCII and MHCI tetramers and characterized the dynamics of virus-
specific CD4 and CD8 T cell responses in vivo. The findings of this study can provide a basis for detailed 
investigation of T cell-mediated immune responses to PVM in a variety of genetically modified C57BL/6 
mice.
Pneumoviruses were formerly assigned to the paramyxoviral subfamily Pneumovirinae, but following a recent 
taxonomy update this subfamily was elevated to family status (the family of Pneumoviridae), and the genus 
Pneumovirus was renamed to Orthopneumovirus1. Members of the Pneumoviridae, are enveloped viruses with 
negative-sense non-segmented RNA genomes. Closely related Orthopneumoviruses, such as human respiratory 
syncytial virus (hRSV), bovine respiratory syncytial virus (bRSV) and pneumonia virus of mice (PVM) are highly 
species-specific and can cause severe respiratory infections in their natural hosts2. Among these, hRSV is one of 
the leading causes of airway morbidity and infant hospitalization worldwide. Therefore, modeling hRSV disease 
in vivo is a crucial first step in the further understanding of antiviral immune responses and the development of 
novel therapies and preventive measures against RSV pathogenesis. So far, most studies have relied on the use of 
hRSV itself to infect inbred laboratory mouse strains, particularly BALB/c, to unravel different aspects of RSV 
pathology3, 4. However, as pneumoviruses display a narrow host range, human RSV does not replicate robustly 
in murine tissue and inadequately reproduces specific features of human RSV disease in mice2, 4, 5. More recently, 
infection of mice with PVM, the natural rodent-specific variant of hRSV, has been proposed as an alternative 
experimental model for human RSV infection6. PVM and hRSV display marked genomic similarity, as every 
hRSV viral protein has a counterpart in PVM even though direct sequence homology is limited7. More impor-
tantly, the PVM infection model accurately mimics many of the clinical and pathological hallmarks of RSV dis-
ease in human infants2, 4.
Even though RSV replicates poorly in mice, several groups have extensively studied many aspects of T cell 
biology using various approaches to induce hRSV-driven disease. Overall, these studies have revealed that T cells 
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contribute to viral clearance, but are also the main drivers of immunopathology8–12. Because of this apparent dual 
role, T cell responses have also been evaluated in the PVM model. A comprehensive study by Frey and colleagues 
illustrated a key role for both CD4 and CD8 T cells in virus control and induction of PVM-mediated disease13. 
In the context of CD4 T cell responses, it was demonstrated that IL21R KO mice survive longer in response to 
PVM infection, suggesting that activated CD4 T cells, the main producers of IL21, may contribute to pathology14. 
Adoptive transfer studies and peptide-immunization studies have revealed that as well as their contribution to 
immunopathology during primary infection, T cells can also provide protection against severe PVM-induced dis-
ease15, 16. Overall, these studies suggest the existence of a tight balance between beneficial and detrimental effects 
caused by T cells during pneumovirus infection, however, underlying molecular mechanisms remain elusive.
The PVM infection model is well-accepted for studying severe RSV-induced disease, however insufficient tools 
are currently in place to study T cell responses in great detail. While hRSV- or PVM- specific T cell epitopes have 
been described particularly for BALB/c (H2d) mice, most transgenic and knockout mice are primarily available 
on a C57BL/6 (H2b) background15, 17–19. Recently, Walsh and colleagues identified PVM-specific H2b-restricted 
CD8 T cell epitopes in C57BL/6 mice20. However, so far, no PVM-specific CD4 T cell epitopes have been identi-
fied in the context of PVM-infected C57BL/6 mice. While T cell kinetics during pulmonary PVM infection have 
been described in response to PVM strain J3666 in BALB/c mice16 and PVM strain 15 in C57BL/6 mice13, to our 
knowledge a detailed kinetic documentation of both CD4 and CD8 T cell responses against PVM strain J3666 
is currently lacking in C57BL/6 mice. Therefore, the aim of this study was to map CD4 T cell epitopes along the 
PVM proteome and determine the dynamics of the PVM-specific CD4 and CD8 T cell response following PVM 
infection in C57BL/6 mice.
Results
Clinical features of disease manifestation and T cell dynamics in response to PVM J3666 infec-
tion in C57BL/6 mice. Two well-characterized strains of PVM, strain 15 and strain J3666, are commonly 
used for research purposes7, 21–23. To investigate the T cell response during PVM disease, we administered a 
sub-lethal dose of PVM strain J3666 intratracheally (i.t) to C57BL/6 mice and weight loss was monitored as a 
clinical measure for disease (Fig. 1a). Mice started to gradually lose body weight at day 7 post-infection (pi), with 
a maximal weight loss of approximately 15% around 10–11 days pi. All mice had recovered from disease around 
14 days pi. Viral load was assessed by means of qRT-PCR on lung tissue and virus RNA was first detectable from 
day 6 pi onwards, with a peak around day 8 pi. This was followed by a phase of viral clearance and virus RNA was 
no longer detected by day 14 pi. The kinetics of weight loss and the viral load determined by qRT-PCR was the 
same as that described by Frey et al. using an infectious virus assay in the analysis of the role of T cells in PVM dis-
ease, with the peak of viral load seen at day 8 pi and the peak of PVM-induced weight loss being most pronounced 
during the phase of virus elimination (Fig. 1a). Finally, PVM-specific antibodies in the serum were detectable at 
day 10 pi and reached maximal titers around 14 days pi, when mice had recovered from disease (Fig. 1a–b).
We used this model to explore the dynamics of the CD4 and CD8 T cell responses upon primary infection, 
both at the site of infection (i.e. lung) and the draining mediastinal lymph node (MLN). The gating strategy used 
to define CD4 and CD8 T cell populations is depicted in Supplementary Fig. S1. The influx of both CD4 and CD8 
T cells in the lung occurred between day 10 and 14 pi, albeit higher numbers of CD8 T cells were detected (Fig. 1c, 
upper panels). A similar course was observed for total numbers of CD4 and CD8 T cells in the bronchoalveolar 
lavage (BAL) (Supplementary Fig. S1). In the MLN, expansion of the CD4 and CD8 T cell populations started 
around day 7–8 pi and numbers were still rising at day 18 pi (Fig. 1c, lower panels). Recruitment of activated 
effector T cells within lung infiltrates was determined by CD44 expression24. The relative proportions of both 
CD44+ effector CD4 and CD8 T cells in the airways of PVM-infected mice started to increase at day 8 pi. From 
day 14 pi onwards, approximately 85% of CD8 T cells and 60% of CD4 T cells in the lung expressed high levels 
of CD44. In contrast, the relative proportions of CD44+ effector T cells in the MLN did not change substantially 
during the course of infection (Fig. 1d and Supplementary Fig. S1). Thus, activated effector T cells were recruited 
to the airways of PVM-infected mice around day 8 and reached maximal levels between day 10 to 14 pi.
In silico prediction of MHCII-restricted PVM epitopes. Having characterized the general T cell 
responses upon PVM infection, we next aimed to study virus-specific T cell dynamics. Walsh and colleagues 
recently identified MHCI-restricted T cell epitopes in PVM-infected C57BL/6 mice, however, MHCII-restricted 
T helper epitopes have not yet been described in the C57BL/6 context. To identify novel PVM-specific CD4 T cell 
epitopes, the amino acid sequence of the PVM strain J3666 proteome was screened for peptides with the potential 
for high MHCII-binding affinity using the Immune Epitope Database (IEDB) and analysis resource Consensus 
tool25, 26. From the output of the online algorithm, the 2 highest-ranked non-overlapping peptides were selected 
for each of the 12 viral PVM proteins. Based on these criteria, a set of 24 predicted peptide sequences was 
obtained, which was evenly distributed along the PVM genome as summarized in Table 1.
Identification of a novel MHCII-restricted PVM epitope M37–47. Next, this panel of 24 predicted 
IAb-restricted PVM epitopes was validated for their capacity to stimulate CD4 or CD8 T cells isolated from 
PVM-infected mice. C57BL/6 mice were i.t. infected with a sub-lethal dose of PVM J3666 and sacrificed at 14 
days pi, at the time of maximal CD4 T cell recruitment to the airways (Fig. 1c). BAL and lung single-cell suspen-
sions were restimulated ex vivo with each of the predicted MHCII-restricted PVM epitopes and cytokine produc-
tion by T cells was evaluated by intracellular staining, using flow cytometry (Fig. 2a). To determine background 
cytokine production, we also restimulated cells without peptide, with an irrelevant MHCII-restricted Derp1128–149 
peptide27 or with a known MHCI-restricted N339–347 epitope20. Of the 24 peptides tested, only the M33–47 peptide 
potently induced IFNγ production above background in CD4 T cells isolated from both lung and BAL (Fig. 2b,c). 
In the lungs, 0.3–0.5% of total pulmonary CD4 T cells responded to peptide M33–47, while in the BAL this was 
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about 9–10% of total CD4 T cells, although background IFNγ levels were also higher in BAL compared to lung 
(Fig. 2b,c). IFNγ+ CD4 T cells expressed high levels of CD44, consistent with an activated state (Fig. 2c). We also 
assessed TNFα production by CD4 T cells and observed a similar cytokine pattern in response to the same panel 
of predicted peptides (Supplementary Fig. S2). Of note, CD8 T cells in the same cultures did not respond to any 
of the peptides summarized in Table 1, except to peptide NP333–347 (Supplementary Fig. S2), which included the 
GAPRNRELF sequence of the MHCI-restricted N339–347 epitope20.
For the development of MHCII tetramers, it was important to exclude that multiple binding registers 
existed within the M33–47 peptide sequence. To verify this, we used another IAb peptide prediction algorithm28. 
Unexpectedly, we identified two overlapping epitopes within the M33–47 peptide sequence. In the context of 
MCHII tetramer design, it was essential to identify the core sequence of the M33–47 peptide. The reason for this is 
that the MHCII:peptide binding is flexible and anchorless. When a tetramer is generated using a peptide that con-
tains overlapping epitopes, the MHCII molecules might display the peptide in different registers. Such a tetramer 
could thus consist of different epitope arms, which would reduce the effectiveness of the tetramer staining because 
of the loss of avidity. We therefore set-out to further identify the most potent core sequence within this immu-
nodominant epitope. Cells isolated from PVM-infected mice were restimulated with two overlapping 11-mer 
peptides, M33–43 (TVWIPMFQTSL) and M37–47 (PMFQTSLPKNS), covering the initially identified 15-mer M33–47 
sequence (TVWIPMFQTSLPKNS). Both in lung and BAL, only M37–47 elicited a robust IFNγ and TNFα response 
in CD4 T cells, albeit slightly less efficient than the full length M33–47, which most likely can be explained by the 
presence of multiple binding registers that activate a mixed pool of T cells (Fig. 2d). Again, no significant cytokine 
Figure 1. Weight change kinetics, viral load and dynamics of T cell responses in PVM-infected mice. 8 week 
old C57BL/6 females were infected i.t. with a sub-lethal dose of PVM strain J3666 and sacrificed at the indicated 
days post-infection. (a) Weight change and viral load kinetics. Open gray squares depict percentage difference 
in mean weight relative to day 0 as depicted by the dotted line (n = 5). Filled dots show expression levels of the 
PVM SH gene relative to L27 as determined by qRT-PCR on lung tissue (n = 3–9 per time point). (b) Percentage 
weight loss (described in a; open squares) and levels of PVM-specific antibodies in serum (filled squares; n = 4 
per time point), represented as the absorbance index relative to a positive control. (c) Absolute numbers of CD4 
(orange) and CD8 (blue) T cells in the lung and MLN, as determined by flow cytometry (n = 5 per time point). 
Gating strategy, see Supplementary Fig. S1. (d) Frequency of CD44+ T cells in lung and MLN as percentage of 
total CD4 (orange) or CD8 (blue) T cells (n = 5 per time point). All results are shown as mean ± SEM and are 
representative of two (a and b) or three (c and d) independent experiments. SH, small hydrophobic protein; 
L27, ribosomal protein L27; MLN, mediastinal lymph node.
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production was detected in CD8 T cells from the same culture (data not shown). Overall, these data demonstrate 
that the M37–47 peptide is an IAb-restricted PVM epitope that is specifically recognized by CD4 T cells from 
PVM-infected C57BL/6 mice.
Kinetics of PVM-specific CD4 and CD8 T cell responses in C57BL/6 mice. To characterize 
the dynamics of PVM-specific CD4 and CD8 T cell responses in C57BL/6 mice using our newly identified 
MHCII-restricted M37–47 epitope and the previously described MHCI-restricted N339–347 epitope20, we gener-
ated peptide-loaded MHCII and MHCI tetramers, which allowed us to track virus-specific CD4 and CD8 T 
cell responses in vivo. Following PVM infection, M37–47-specific CD4 T cells in the lung were detectable at low 
levels at day 10 pi, reached a maximum of 1.8% on average among the total CD4 T cell pool at day 14 pi and 
declined again by day 18 pi. The N339–347-specific CD8 T cells exhibited a marked infiltration from day 10 pi 
onwards, representing up to 19.6% on average of all CD8 T cells at the peak of disease severity, and then gradu-
ally decreased (Fig. 3a,b). In Fig. 3B this is also illustrated as total numbers of tetramer-positive CD4 or CD8 T 
cells. Virus-specific CD4 and CD8 T cells displayed high expression levels of CD44 compared to the total CD4 
and CD8 T cell pool, suggesting that they exhibit critical effector functions during the course of PVM infection 
(Fig. 3c). Staining of the PVM-specific M37–47 MHCII tetramer was virus-specific as CD4 T cells isolated from the 
airways of Influenza virus strain X31-infected mice did not show increased tetramer staining neither at day 14 
(peak PVM CD4 T cell response), nor at day 8 (marked CD8 and CD4 T cell response against Influenza29), even 
though NP366–374 MHCI tetramer-positive Influenza-specific CD8 T cells30 were clearly detectable at both time 
points (Supplementary Fig. S3). From these data, we conclude that the modest appearance of M37–47-specific CD4 
T cells in the airways from day 10 pi onwards is slightly delayed compared to the marked influx of N339–347-specific 
CD8 T cells at that same time point.
Discussion
There is growing interest in the use of the natural mouse pathogen PVM to mimic and study severe pneumo-
virus disease. T cells play a key role in both pneumovirus clearance and disease induction, but there is a lack of 
tools to study T cell responses in great detail in C57BL/6 mice, which limits the use of genetically modified mice 
derived from this lineage. We therefore set out to identify a PVM-specific CD4 T cell epitope in C57BL/6 mice. 
By means of in silico prediction and subsequent functional validation, we were able to reveal an IAb-restricted 
Peptide sequence Protein1
Position Percentile 
rank2Start End
CNLLRPFVQAAKFIH NS1 57 71 15,14
QTLTHWFTKNIVFSS NS1 77 91 18,73
MNKFTQTISKPATIL NS2 5 19 4,62
LLIEKFQPSLQNITR NS2 49 63 6,43
IIGSYKGAPRNRELF NP 333 347 9,68
VEGLFSGLFMNAYGA NP 239 253 10,75
TIMVATAGPTTARDE P 198 212 1
LRSSFKLPSPRVAAN P 51 65 1,52
LLQILLNPLLPLPLH P2 22 36 5
LTIRNTARSHAAQMI P2 64 78 6,87
PKNMLYTVPSITPTN M 122 136 1,89
TVWIPMFQTSLPKNS* M 33 47 4,95
CTVHPNHPPPSYGVN SH 64 78 4,4
QKLSFNKPQARQLYP SH 98 112 8,59
MGRNFEVSGSITNLN G 1 15 2,16
TIPRFTKPPTKTATH G 94 108 4,44
LVIFNTKPIHPNTLT F 11 25 5,18
ISTSKTYVSTAVLTT F 358 372 6,99
KYSHKYWEWPLKTLM M2-1 21 35 11,73
NRIYRFLDTNTDAMS M2-1 43 57 15,75
NLTYDGSGPSTIIDA M2-2 44 58 0,65
MIRLPKYYPAILHKM M2-2 22 36 7,14
QHMFLPNHITPAQYI L 1378 1392 2,02
VPMQFGGADPNVIYR L 926 940 2,54
Table 1. Predicted MHCII-restricted PVM epitopes. 1PVM proteins: Non-structural protein (NS1 and 2), 
Nucleoprotein (NP), Phosphoprotein (P, P2), Matrix protein (M, M2-1, M2-2), Small hydrophobic protein (SH), 
Attachment glycoprotein (G), Fusion protein (F), RNA polymerase (L). 2The MHCII binding predictions were 
performed using the IEDB analysis source Consensus tool. The lower the percentile rank, the better the binders. 
*Shows 100% homology to PVM strain 15; the underlined region delineates the core epitope M37–47, contained 
within the M33–47 sequence.
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epitope, corresponding to amino acids 37-47 at the N-terminal end of the PVM matrix protein. According to 
published sequences, the M37–47 epitope PMFQTSLPKNS is completely conserved in both PVM strain J3666 and 
strain 157, 31. In comparison, IAb-restricted CD4 T cell epitopes in the RSV proteome have also been mapped to 
the M protein (M213–223), as well as to the M2 (M227–37) and G protein (G168–185)32–35. We demonstrated that the 
M37–47 peptide exclusively stimulated virus-specific CD4 T cells, and not CD8 T cells, and induced IFNγ pro-
duction in 0.2-0.3% of total CD4 T cells in the lungs. This is equivalent to the range obtained from hRSV CD4 
Figure 2. Identification of MHCII-restricted PVM epitopes recognized by CD4 T cells from PVM-infected 
mice. 8 week old C57BL/6 females were infected i.t. with a sub-lethal dose of PVM strain J3666 and sacrificed 
14 days later. BAL and lung single-cell suspensions were restimulated for 6 h in the presence of Golgistop 
and PVM-specific peptides. T cells were evaluated for cytokine production by intracellular staining and flow 
cytometry analysis. (a) Schematic overview of the experimental setup and gating strategy to identify CD4 
and CD8 T cell populations in BAL and Lung. (b–d) IFNγ or TNFα production by CD4 T cells, isolated from 
lung or BAL, after incubation with each of the predicted MHCII-restricted PVM peptides enlisted in Table 1. 
As negative controls, cells were incubated without peptide, with an irrelevant Derp1 CD4 peptide27, or with 
a MHCI-restricted PVM N339–347 peptide20 and are shown in gray. (b) IFNγ production by CD4 T cells in 
BAL and Lung. Data are depicted as frequency of IFNγ-producing cells among total CD4 T cells. (c) Left, 
representative FACS plots (gated on CD4+ cells) show the percentage of IFNγ+ CD4 T cells in response to 
restimulation with or without M33–47 peptide. Right, Histogram overlays depict CD44 expression levels of total 
CD4+ and gated IFNγ+ CD4+ populations (marked orange in left panel) following restimulation with M33–47 
peptide. Data are normalized to and depicted as the percentage of the maximum count (% of max on the Y 
axis). (d) IFNγ and TNFα production by CD4 T cells following restimulation with M33–47, M33–43, or M37–47. 
Results are shown as mean ± SEM from three biological replicates. For each biological replicate 10 mice were 
pooled to obtain sufficient cell numbers for epitope screening. Data are representative of two independent 
experiments. For statistics, conditions restimulated with peptide were compared to the no-peptide control (b, 
Student’s t test with Welch correction) or the M33–47 peptide (d, ANOVA for multiple comparisons) as indicated. 
BAL, bronchoalveolar lavage; IFNγ, interferon gamma; TNFα, tumor necrosis factor alpha; MHCI/II, major 
histocompatibility complex class I or II; Derp1, Dermatophagoides pteronyssinus peptidase 1; Irr, irrelevant; ns, 
not significant.
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epitope mapping studies in C57BL/632. Although we did not perform direct comparisons in the same mice, we 
observed that the frequencies of IFNγ+ CD4 T cells after M37–47 peptide stimulation were consistently lower than 
frequencies identified by MHCII tetramers loaded with the same peptide. A possible explanation is that some of 
the antigen-specific T cells produce cytokines other than IFNγ and TNFα or maybe T cell exhaustion occurs36. 
On the other hand, this observation might also resemble the so-called functional inactivation phenotype that has 
been described for CD8 T cells upon hRSV and simian virus 5 infection17, 37–39. It is tempting to speculate that 
viruses from the Pneumoviridae and Paramyxoviridae families functionally inactivate all T cell subsets, though 
more studies are needed to address this in detail.
In this work, MHCII binding predictions for each major PVM protein were performed by means of the IEDB 
analysis resource tool. However, because of the less strict binding requirements and the limited predictive value 
of MHCII motifs, this in silico approach may lead to an overall lower prediction accuracy compared to MHCI 
binding predictions26, 40. No direct correlation between the IEDB-predicted percentile ranks and the percentage 
of IFNγ+ T cells elicited by each of these peptides was observed (Table 1). For instance, the top hit M2-244–58 pep-
tide, as reflected by a low percentile rank of 0.65, did not elicit any response in our functional screen. In contrast, 
The M33–47 epitope only had a moderate percentile rank of 4.95 but induced solid CD4-specific T cell responses 
(Fig. 2b). As we have tested only 24 peptides (the 2 highest-ranked non-overlapping peptides for each of the 12 
viral proteins) it is possible that the lower-ranked IEDB-predicted epitopes may harbor additional CD4 epitopes. 
Likewise, we cannot exclude that other peptide epitopes exist that are not predicted by the IEDB algorithm, as 
was shown for hRSV18.
Figure 3. In vivo characterization of the virus-specific CD4 and CD8 T cell response in PVM-infected mice. 
7 week old C57BL/6 females were infected i.t. with a sub-lethal dose of PVM strain J3666 or were used as 
uninfected controls (day 0). At the indicated time points post-infection, virus-specific CD4 and CD8 T cells in 
the lung were identified by flow cytometry, using M37–47 and N339–347 peptide-loaded MHC class II and MHC 
class I tetramers. (a) Representative FACS plots of manually gated CD4 T cells (upper panels) or CD8 T cells 
(lower panels) show percentages of M37–47-tetramer+ CD4 T cells or N339–347-tetramer+ CD8 T cells (respectively 
marked orange or blue at 14 dpi). (b) Absolute numbers of M37–47-tetramer+ CD4 T cells (left panel) or 
N339–347-tetramer+ CD8 T cells (right panel). Results are shown as mean ± SEM, each data point represents one 
individual mouse (n = 4). (c) Histogram overlays show CD44 expression of total CD4 or CD8 T cells versus their 
respective tetramer+ populations at day 14 post-infection. M37–47-tetramer+ CD4 T cells and N339–347-tetramer+ 
CD8+ T cells, marked orange and blue, are gated as shown in (a). Data are normalized to and depicted as the 
percentage of the maximum count (% of max on the Y axis). Data are representative of three independent 
experiments. For statistics (Student’s t test with Welch correction), PVM-infected mice were compared to non-
infected controls (day 0) as indicated.
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In addition to the identification of an IAb-restricted epitope, we also performed a comprehensive kinetic anal-
ysis for both CD4 and CD8 T cell responses against PVM strain J3666 in C57BL/6 mice, which to the best of our 
knowledge was lacking at the time. We showed that acute PVM infection in C57BL/6 mice is associated with a 
large influx of activated CD4 and CD8 T cells in the lung and BAL from day 10 pi onwards, coinciding with the 
phase of virus elimination (Fig. 1a and Supplementary Fig. S1). Another study in C57BL/6 mice describes the 
appearance of total CD3 T cells in the alveolar space as soon as day 8 pi13. However, it should be noted that PVM 
strain 15 was used, which might explain the slight difference in kinetics. Also, in the BALB/c model, van Helden 
and colleagues describe a marked influx of CD8 T cells from day 10 onwards following PVM J3666 infection, 
similar to what we observe in C57BL/6 mice16. Together, these data suggest that the PVM virus induced a strong 
antiviral T cell response and as such might indeed play a dual role in both viral clearance and PVM-induced 
immunopathology as was demonstrated by others13, 16. Using the newly identified MHCII-restricted M37–47 
epitope and the previously described MHCI-restricted N339–347 epitope, we generated fluorochrome-conjugated 
MHCII and MHCI tetramers, allowing us to track PVM-specific CD4 and CD8 T cells, respectively. We showed 
that the appearance of M37–47-specific CD4 T cells in the airways was slightly delayed compared to N339–347-specific 
CD8 T cells, though we currently do not know if this is a general feature for all PVM-derived epitope-specific 
CD4 versus CD8 T cell responses.
To conclude, this is the first study that demonstrates a detailed kinetic analysis of both CD4 and CD8 T cell 
responses against PVM strain J3666 in infected C57BL/6 mice. Moreover, the M37–47 MHCII-restricted epitope 
identified in this work, provided the basis for the development of fluorescently-labeled MHCII-peptide tetramers 
that serve as valuable tools to track PVM-specific T cells during the course of infection. Such tools will facilitate 
more detailed investigations of T-cell mediated immune responses to PVM in a variety of genetically modified 
C57BL/6 mice. In this respect, the use of the PVM model in general holds great promise to improve our under-
standing of pneumovirus-associated disease and may assist in the development of peptide-based vaccines and 
other novel prevention strategies.
Methods
Mice, virus stock and infection. Mouse-passaged stocks of PVM strain J3666 were grown as described23. 
Age-matched 7-9 week old female C57BL/6 mice were purchased from Janvier (Saint-Berthevin, France), anes-
thetized with isoflurane (2 l/min, 2-3%) and then infected intratracheally with a previously in vivo titrated sub-le-
thal dose of PVM in 80 µl PBS. Infections were performed intratracheally instead of the standard intranasally 
(i.n.) procedure in order to minimize variations. We did not observe any differences in disease severity (e.g. 
weight loss) between i.t. or i.n. instillations. For Influenza experiments, mice were infected i.n. with 103 TCID50 
H3N2 Influenza strain X31 virus in a total volume of 50 µl PBS. All experimental procedures were in accordance 
with institutional guidelines for animal care of the VIB site Ghent – Ghent University, Faculty of Sciences and 
were approved under accreditation n° EC2013-035 and EC2015-016.
Tissue sampling and processing. Mice were sacrificed at time points indicated by intraperitoneal (i.p.) 
injection of sodium pentobarbital. To detect PVM-specific antibodies in the serum, blood was collected in a 
regular Eppendorf tube, centrifuged at 500 xg for 10 min at room temperature (RT) and the supernatant was 
stored at −20 °C. Bronchoalveolar lavage (BAL) fluid was collected by three subsequent injections of 1 ml PBS 
containing 1 mM EDTA via a tracheal catheter. Before isolation, lungs were perfused with 10 ml PBS through 
the right heart ventricle. The lungs were then mechanically disrupted by GentleMACS dissociation (Miltenyi 
Biotec) (Lung program 01_01) in RPMI 1640 (Gibco) containing 20 µg/ml Liberase and 10 U/ml Dnase (Roche), 
followed by digestion for 30 min at 37 °C and final GentleMacs homogenization (Lung program 02_01). Next, 
the cell suspension was passed through a 100 µm filter and red blood cells were lysed using ammonium chloride 
lysis buffer (10 mM KHCO3, 155 mM NH4Cl, 0,1 mM EDTA in MilliQ water). For RNA isolation, the lower 
left lung lobe was collected in 1 ml TriPure (Roche) and stored at −80 °C. The mediastinal lymph node (MLN) 
was sterile-smashed over a 70 µm filter in PBS and collected in a final volume of 250 µl PBS. Cell counts were 
performed either manually by microscopy using trypan blue and a Bürker Türk counting chamber (Marienfeld, 
Germany) or automatically by adding 20.000 BD Calibrite beads (BD Biosciences) to the cell pellet and subse-
quent flow cytometry analysis.
Epitope prediction and peptides. MHCII binding predictions were performed on 9/25/2013 using 
the IEDB analysis resource Consensus tool41, 42. The amino acid sequences of all 12 PVM J3666 viral pro-
teins (Genbank RefSeq accession numbers YP_173324.1-YP_173335.1)31 were screened for predicted 
epitopes in the H2-IAb alleles using the default IEDB recommended prediction method. For every PVM pro-
tein, the 2 highest-ranked non-overlapping peptides were selected and synthesized. A summary of the 24 
selected epitopes and their sequences is provided in Table 1. In addition to the predicted peptides shown in 
Table 1, the following peptides were used: M33–43, TVWIPMFQTSL; M37–47, PMFQTSLPKNS; Derp1128–149, 
GCGSCWAFSGVAATESAYLAYR27; N339–347, GAPRNRELF20. The M33–43 and M37–47 overlapping epitopes within 
the M33–47 peptide sequence were predicted using another IAb peptide algorithm28. All peptides were synthesized 
by GenScript (Piscataway, USA), using standard chemical peptide synthesis service. The purity varied between 
75% and 90%, however, for the M33–43, M37–47 and M33–47 peptides it was around 90%. M33–43 was dissolved in 10% 
DMSO, whereas M37–47 and M33–47 were dissolved into ultrapure water.
Cell culture reagents and restimulation. For peptide restimulation experiments, BAL and lung 
single-cell suspensions (day 14 post-infection) were resuspended in sterile tissue culture medium (TCM) sup-
plemented with 5,7% FCS (Bodinco), 1.1 mg/ml β-Mercaptoethanol (Sigma), 56 μg/ml Gentamicin (Gibco) 
and 1% L-Glutamine (Gibco). To assess intracellular IFNγ production, 4 × 105 BAL and 2 × 106 lung cells were 
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restimulated for 6 h at 37 °C in 100 µl TCM containing 10 µg/ml peptide and 0.07% Golgistop (BD Pharmingen) 
in round-bottom 96-well plates. For control conditions, 10 µg/ml Derp1128–149 peptide or 2 µg/ml N339–347 peptide 
were added. Three biological replicates were performed, for which 10 mice per replicate were pooled to obtain 
sufficient cell numbers.
Flow cytometry. Fluorochrome-conjugated antibodies were purchased from eBioscience (Temse, Belgium) 
[anti-CD8 eFluor450 (53-6.7), anti-CD45 APC (30-F11), anti-CD3 PE (145-2C11) and AF700 (17A2), anti-CD44 
PeCy7 (IM7), anti-IFNγ PeCy7 (XMG1.2)]; BD Biosciences (Erembodegem, Belgium) [anti-CD4 BV605 (RM4-
5) and anti-TNFα FITC (MP6-XT22)]; Tonbo Biosciences (San Diego, California) [anti-CD44 Redfluor710 
(IM7)]. Viable cells were discriminated by the use of Fixable Viability dye eFluor780 (eBioscience). Cell sur-
face markers were stained for 20 min at 4 °C. For peptide restimulation experiments, extracellular staining was 
followed by fixation and permeabilization using the CytoFix/CytoPerm solution and Perm/Wash buffer (BD 
Biosciences) according to the manufacturer’s protocol and intracellular IFNγ and TNFα staining was performed 
for 30 min at 4 °C. PE-conjugated MHCI-N339–347 (GAPRNRELF) and MHCI-NP366–374 (ASNENMETM) tetram-
ers were purchased from Sanquin (Amsterdam, The Netherlands). PE-labeled MHCII-M37–47 (PMFQTSLPKNS) 
tetramers were generated as described previously43. For tetramer staining, cells were incubated with MHCI (1:15 
dilution) or MHCII (10 nM) tetramer for 1 h at RT and then stained for surface markers for 20 min at 4 °C. Cells 
were acquired on a Fortessa cytometer equipped with FACSDiva software (BD Biosciences). Final analysis and 
graphical output were performed using FlowJo software (LLC, Ashland, OR).
Viral load and PVM-specific ELISA. For viral load quantification by qRT-PCR, lungs were frozen lungs in 
TriPure, thawed and subsequently homogenized using the Tissuelyser II (Qiagen, Hilden, Germany). Total lung 
RNA was purified using TriPure isolation reagent (Roche Diagnostics) and converted to cDNA (iScript Advanced 
cDNA synthesis kit; Bio-Rad Laboratories), according to the manufacturer’s instructions. Quantification 
of PVM virus SH gene RNA and the L27 housekeeping gene was performed using the Maxima Probe qPCR 
Master Mix (Fermentas), hydrolysis probes (Universal probe library, Roche) and primers (IBD)44. Primer and 
probe sets were as follows: L27 set, Universal probe library #3, Fw primer TGAAAGGTTAGCGGAAGTGC, 
Rev primer CATGAACTTGCCCATCTCG; PVMSH set, Universal probe library #66, Fw primer 
CACCAGATCACCCTCGAGAT, Rev primer GGGCTGGTGTAGTGTATGTGC, and results were also vali-
dated using a second PVMSH set, Universal probe library #22, Fw primer AATGCACAGTTCATCCCAATC, 
Rev primer TTACCCGGCAGACCAGTTAC. Reactions were performed in a LightCycler 480 (Roche) at 95 °C 
for 10 min, 45 cycles of 95 °C for 10 s, 60 °C for 30 s, 72 °C for 1 min and a final cycle of 40 °C for 30 s. Data were 
analyzed using the qBase software (Biogazelle, Belgium) and PVMSH expression levels were normalized to L27. 
PVM-specific IgG were measured in serum using the SMART M12 kit (Biotech Trading Partners, Encinitas, 
California), following the manufacturer’s instructions. Read-out was performed by spectrophotometry and data 
are represented as the absorbance index relative to a positive control.
Statistical analysis. All experiments were performed using three to five animals per group, unless men-
tioned otherwise. Statistical analyses were performed using the two-tailed Student’s t test for unpaired data 
(with Welch correction assuming unequal variances) or one-way ANOVA (with Dunnett correction for mul-
tiple comparisons), making use of Prism version 7.01 (GraphPad Software, La Jolla, CA). Error bars represent 
standard error of the mean (SEM). Levels of significance are expressed as p-values (ns, not significant; *P < 0.05; 
**P < 0.01; ***P < 0.001; ****P < 0.0001).
Data availability. All data generated or analysed during this study are included in the published article (or 
its Supplementary files).
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